EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review

Abdulrahman Ismaiel iD, Vera Ciornolutchii, Stefan-Lucian Popa, Dan L Dumitrascu

European Journal of Clinical Investigation · 2026

DOI: 10.1111/eci.70185 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift European Journal of Clinical Investigation, 2026. Verfasst von Abdulrahman Ismaiel und 3 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Internal Medicine, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania. Hauptthemen laut MEDLINE: Dipeptides, Ammonia, Non-alcoholic Fatty Liver Disease, Hyperammonemia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

While hyperammonemia is traditionally associated with decompensated cirrhosis, emerging evidence suggests that disturbances in nitrogen homeostasis contribute to disease progression in earlier stages of steatohepatitis and fibrosis. L‐ornithine L‐aspartate (LOLA), an established ammonia scavenger, targets key pathophysiological mechanisms shared by metabolic dysfunction‐associated steatotic liver disease (MASLD), including oxidative stress, mitochondrial dysfunction and hepatic stellate cell activation. This systematic review synthesizes current experimental and clinical research to evaluate the potential therapeutic role of LOLA in MASLD.

Methods

A systematic search of PubMed, Embase and SCOPUS was conducted up to December 1, 2025, following PRISMA 2020 guidelines. Eligible studies included experimental (in vivo/in vitro) and clinical trials evaluating the effects of LOLA or L‐aspartate on hepatic steatosis, inflammation, or fibrosis in the context of MASLD. Data extraction and quality assessment were performed independently by two reviewers using appropriate tools for animal and human studies.

Results

Nineteen studies were included, comprising 10 experimental pre‐clinical models (9 in vivo animal studies and 1 in vitro study) and 9 clinical studies involving approximately 1671 participants. Experimental studies consistently demonstrated that LOLA intervention ameliorates hepatic steatosis, inflammation and collagen deposition. Identified molecular mechanisms included the activation of the LKB1‐AMPK axis, restoration of mitochondrial bioenergetics and modulation of the gut‐liver‐muscle axis. In clinical studies, results from three randomized controlled trials (RCTs) indicated significant improvements in liver enzymes (ALT, AST) and lipid profiles, with reductions in hepatic steatosis. Evidence from six observational and open‐label studies corroborated these biochemical improvements and further demonstrated significant reductions in blood ammonia levels, improved intrahepatic microcirculation and reduced liver stiffness and patient‐reported fatigue. However, clinical evidence remains limited by study heterogeneity and a lack of large‐scale randomized trials using specific MASLD criteria.

Conclusions

Preclinical evidence suggests that LOLA exerts pleiotropic hepatoprotective effects in MASLD by targeting hyperammonemia‐induced fibrosis and metabolic dysregulation. While growing clinical data indicate benefits in biochemical normalization, structural improvement and symptom relief, further robust clinical research is required to validate these findings and establish LOLA as a standard therapeutic option for MASLD patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DipeptidesAmmoniaNon-alcoholic Fatty Liver DiseaseHyperammonemiaFatty LiverHumansAnimalsLiver CirrhosisOxidative Stress

Stichwörter der Autor:innen

AMPK signallingL‐ornithine L‐aspartateammonia scavenginghepatic fibrosismetabolic dysfunction‐associated steatotic liver diseasemetabolic‐dysfunction associated steatohepatitis

Substanzen

ornithylaspartateDipeptidesAmmonia

Autor:innen und Institutionen

  • 2nd Department of Internal Medicine, 'Iuliu Hatieganu' University of Medicine and Pharmacy, Cluj-Napoca, Romania.

ORCID-Profile: Abdulrahman Ismaiel

Zitieren

APA

Ismaiel, A., Ciornolutchii, V., Popa, S. L., & Dumitrascu, D. L. (2026). Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70185

Vancouver

Ismaiel A, Ciornolutchii V, Popa SL, Dumitrascu DL. Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review. European Journal of Clinical Investigation. 2026. doi:10.1111/eci.70185

BibTeX
@article{Ismaiel2026,
  author = {Ismaiel, Abdulrahman and Ciornolutchii, Vera and Popa, Stefan-Lucian and Dumitrascu, Dan L},
  title = {Can ammonia scavenging treat MASLD? Evaluating the evidence for L‐ornithine L‐aspartate—A systematic review},
  journal = {European Journal of Clinical Investigation},
  year = {2026},
  doi = {10.1111/eci.70185}
}
Kostenlos starten →